$
9.410
+0.06(0.642%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.420
Open
9.380
VWAP
9.36
Vol
5.03M
Mkt Cap
11.04B
Low
9.290
Amount
47.10M
EV/EBITDA(TTM)
5.54
Total Shares
1.19B
EV
24.30B
EV/OCF(TTM)
10.93
P/S(TTM)
0.78
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
3.49B
-1.09%
0.560
+3.66%
3.61B
-3.79%
0.614
-18.1%
3.46B
-8.98%
0.556
-19.9%
Estimates Revision
The market is revising Upward the revenue expectations for Viatris Inc. (VTRS) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 14.06%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.6%
In Past 3 Month
Stock Price
Go Up
up Image
+14.06%
In Past 3 Month
3 Analyst Rating
down Image
-4.36% Downside
Wall Street analysts forecast VTRS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
1 Sell
Moderate Sell
down Image
-4.36% Downside
Current: 9.410
sliders
Low
8.00
Averages
9.00
High
10.00
Goldman Sachs
Neutral
initiated
$10
2025-06-06
Reason
Goldman Sachs initiated coverage of Viatris with a Neutral rating and $10 price target. The firm awaits clarity on the company's growth outlook given current structural dynamics in the core business and believes consensus estimates appear fair. On the generics side, it expects modest growth as Goldman monitors Viatris' ability to more meaningfully off-set legacy product erosion via new product launches and portfolio optimization.
Jefferies
Glen Santangelo
Strong Buy
Maintains
$15 → $13
2025-03-07
Reason
Piper Sandler
David Amsellem
Hold
Reiterates
$14 → $10
2025-03-05
Reason
Piper Sandler analyst David Amsellem lowered the firm's price target on Viatris to $10 from $14 and keeps a Neutral rating on the shares after hosting a dinner with senior leadership and investors. The firm came away with a better understanding of the company's challenges out of its manufacturing facility in Indore, India. Taking a step back, Piper says that though it would be tempting to assert that shares are now trading at an attractive risk/reward profile at an EV/2025 EBITDA of 6-turns and in the context of what in its view are resolvable manufacturing issues, it would be equally tempting to assert that the lack of visibility into a clear growth catalyst could translate into the shares trading sideways for the foreseeable future.
B of A Securities
Jason Gerberry
Sell
Maintains
$11 → $10
2025-02-28
Reason
Barclays
Balaji Prasad
Sell
Maintains
$12 → $9
2025-02-28
Reason
Piper Sandler
David Amsellem
Hold
Reiterates
$13 → $14
2024-12-06
Reason

Valuation Metrics

The current forward P/E ratio for Viatris Inc (VTRS.O) is 4.12, compared to its 5-year average forward P/E of 3.87. For a more detailed relative valuation and DCF analysis to assess Viatris Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
3.87
Current PE
4.12
Overvalued PE
4.44
Undervalued PE
3.30

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.05
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.70
Undervalued EV/EBITDA
5.40

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.87
Current PS
0.00
Overvalued PS
1.03
Undervalued PS
0.71

Financials

Annual
Quarterly
FY2025Q1
YoY :
-11.17%
3.25B
Total Revenue
FY2025Q1
YoY :
-56.14%
196.00M
Operating Profit
FY2025Q1
YoY :
-2770.76%
-3.04B
Net Income after Tax
FY2025Q1
YoY :
-2933.33%
-2.55
EPS - Diluted
FY2025Q1
YoY :
-18.57%
459.10M
Free Cash Flow
FY2025Q1
YoY :
-9.90%
37.94
Gross Profit Margin - %
FY2025Q1
YoY :
-5.49%
12.92
FCF Margin - %
FY2025Q1
YoY :
-3105.79%
-93.48
Net Margin - %
FY2025Q1
YoY :
-100.00%
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
346.7K
USD
1
0-12
Months
7.0M
USD
7
Bought
0-3
1
536.3K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 247.32% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
8.3M
Volume
2
6-9
Months
2.4M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
215.7K
Volume
Months
6-9
2
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.0K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
8.0K
USD
Months
6-9
1
8.0K
USD
Months
0-12
0
0.0
USD
Months

VTRS News & Events

Events Timeline

2025-07-24 (ET)
2025-07-24
08:23:28
Bausch Health appoints Michael Goettler, Sandra Leung to board
select
2025-07-18 (ET)
2025-07-18
07:01:30
Viatris announces pimecrolimus trial did not meet primary endpoint
select
2025-06-26 (ET)
2025-06-26
06:05:34
Theravance Biopharma announces Viatris approval for Yupelri in China
select
Sign Up For More Events

News

7.0
07-25Benzinga
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
8.0
07-22MarketWatch
10 dividend stocks with yields up to 6.92% and cash flow to increase payouts
8.0
07-21NASDAQ.COM
Agree To Buy Viatris At $5, Earn 3% Using Options
Sign Up For More News

FAQ

arrow icon

What is Viatris Inc (VTRS) stock price today?

The current price of VTRS is 9.41 USD — it has increased 0.64 % in the last trading day.

arrow icon

What is Viatris Inc (VTRS)'s business?

arrow icon

What is the price predicton of VTRS Stock?

arrow icon

What is Viatris Inc (VTRS)'s revenue for the last quarter?

arrow icon

What is Viatris Inc (VTRS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Viatris Inc (VTRS)'s fundamentals?

arrow icon

How many employees does Viatris Inc (VTRS). have?

arrow icon

What is Viatris Inc (VTRS) market cap?